Skip to main content

6 Result(s)

within Paul Gillard Remove this filter

and
Your search also matched 3 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you. results, e.g.

The class Steiner minimal tree problem: a lower bound and test problem generation

Include preview-only content

  1. Article

    Open Access

    RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

    To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib according to RECIST 1.1, Choi, and modified Choi (mChoi) criteria in patients with metastatic colorectal cancer (mCRC).

    Olivier Lucidarme, Mathilde Wagner, Paul Gillard, Stefano Kim… in Cancer Imaging (2019)

    Download PDF (1017 KB) View Article

  2. Article

    Open Access

    Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

    A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous...

    Saul N. Faust, Maguelone Le Roy, Chitsanu Pancharoen… in BMC Pediatrics (2019)

    Download PDF (1560 KB) View Article

  3. Article

    Open Access

    Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study

    Older individuals often have a reduced immune response to influenza vaccination, which might be improved by administering a higher vaccine dose. We compared the immune response to two single doses of the AS03A-ad...

    Paul Gillard, Didier Giet, Stéphane Heijmans, Mamadou Dramé, Karl Walravens… in Trials (2014)

    Download PDF (989 KB) View Article

  4. Article

    Open Access

    Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults

    The pandemic potential of avian influenza A/H5N1 should not be overlooked, and the continued development of vaccines against these highly pathogenic viruses is a public health priority.

    Paul Gillard, Daniel Wai Sing Chu, Shinn-Jang Hwang… in BMC Infectious Diseases (2014)

    Download PDF (311 KB) View Article

  5. Article

    Open Access

    Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials

    Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity betwe...

    Odile Launay, Xavier Duval, Serge Fitoussi, Wolfgang Jilg… in BMC Infectious Diseases (2013)

    Download PDF (979 KB) View Article

  6. Article

    Open Access

    Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18–60 and >60 years: a randomized trial

    Flexibility of vaccination schedule and lower antigen content can facilitate pandemic vaccine coverage. We assessed the immune response and safety of AS03-adjuvanted A/California/7/2009 H1N1 pandemic vaccine c...

    Xavier Duval, Adrian Caplanusi, Henri Laurichesse… in BMC Infectious Diseases (2012)

    Download PDF (424 KB) View Article